Glanbia Plc · EURONEXT:GL9
Glanbia — Q1 2025 Earnings Presentation
10 slides from Glanbia's earnings presentation, Apr 30, 2025
Slide 1: Q1 2025 Interim Management Statement
Q1 2025 Interim Management Statement 30 April 2025 Hugh McGuire Mark Garvey Chief Executive Officer Chief Financial Officer
Slide 2: Important Notice
Important Notice This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both economic and busi
Slide 3: Q1 2025 – Highlights
Q1 2025 – Highlights • Q1 Group performance in line with expectations • Strong momentum in Health & Nutrition with volume growth in both the premix and flavours solutions businesses • Good progress on mitigating short-term input cost inflation in Performance Nutrition • Continue to progress the Grou
Slide 4: Performance Nutrition ("PN")
Performance Nutrition (“PN”) Revenue growth* (6.6%) Volume (5.8%) Price (0.8%) ▪ LFL** revenue -13.2% in Americas and +6.1% in International ▪ LFL** revenue -4.8% excluding SlimFast and Body & Fit ▪ Volume decline driven by lower revenues in the club and specialty channels in the US and non-core bra
Slide 5: Health & Nutrition ("H&N")
Health & Nutrition (“H&N”) Revenue growth* +24.9% Volume +6.0% Price (0.4%) Acquisitions 19.3% ▪ Volume increase driven by strong growth across both premix and flavour solutions businesses ▪ Pricing in line with expectations ▪ Continued strong growth from Flavor Producers, which was acquired in Apri
Slide 6: Dairy Nutrition ("DN")
Dairy Nutrition (“DN”) Revenue growth* +18.9% Volume +3.6% Price +15.3% ▪ Volume increase driven by continued strong demand for protein solutions ▪ Pricing increase driven by favourable dairy market pricing ▪ Joint Ventures are performing in line with expectations ▪ Dairy Nutrition to be a standalon
Slide 7: Progressing the Group-Wide Transformation Programme
Progressing the Group-Wide Transformation Programme Q1 2025 Progress 1 ✓ Dairy Nutrition to be stood up as a standalone business by 1st July 2025 Operating Model Optimisation ✓ Streamlined PN Americas operating model 2 Unlocking Supply Chain ✓ Chief Supply Chain Officer appointed Efficiencies ✓ Acce
Slide 8: Strong Balance Sheet
Strong Balance Sheet Debt Capital Expenditure Shareholder Returns Net Debt $578.8 million FY25 capex expected to €42.7m returned via be $80m – $90m share buybacks to date* Total committed facilities of $1.3bn Additional €100m authority available 8 || Glanbia plc Q1 2025 IMS Presentation *€42.7m repu
Slide 9: 2025 Outlook
2025 Outlook Reaffirming 2025 guidance based on current tariff environment Revenue Earnings Capital growth growth allocation PN LFL revenue* broadly in line with PN EBITDA margin 13% - 14% OCF conversion 80%+ 2024 H&N EBITDA margin 17% - 18% €50m buyback ongoing with H&N LFL revenue growth* of mid-
Slide 10: Q&A
Q&A A performance driven purpose led global nutrition company 10 || Glanbia plc Q1 2025 IMS Presentation